Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: Study design and baseline characteristics of the 'Watchful Waiting' Study

Anti-Cancer Drugs

Volumn 14, Issue 8, 2003, Pages 595-600

  Stratton, M S ^a   Reid, M E ^b   Schwartzberg, G ^a   Minter, F E ^a   Monroe, B K ^a   Alberts, D S ^a   Marshall, J R ^b   Ahmann, F R ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Prostate cancer; Selenium; Watchful Waiting Study

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SELENIUM; SELENIZED YEAST; UNCLASSIFIED DRUG;

AGED; APOPTOSIS; BLOOD; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GENDER; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL DECISION MAKING; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE TUMOR; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCREENING; STUDY; TUMOR BIOPSY; YEAST;

AGED; ANTICARCINOGENIC AGENTS; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SELENIUM; YEASTS;

EID: 0142061650     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200309000-00004     Document Type: Review

References (47)

1. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs Jr GF, Slate EH, Fischbach LA, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002; 11:630-639.
2. Crawford ED. The utility of prostate-specific antigen as a surrogate marker for identification of high-risk cohorts and assessing response in chemoprevention trials. Eur Urol 1999; 35:511-514.
3. Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, et al. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J Urol 2002; 167:1306-1309.
4. Hammerer P, Semjonow A. [10 years PSA-chemoprevention]. Urologe A 2000; 39:302-303.
5. Crane CH, Rich TA, Read PW, Sanfilippo NJ, Gillenwater JY, Kelly MD. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys 1997; 39:681-686.
6. Narain V, Cher ML, Wood Jr DP. Prostate cancer diagnosis, staging and survival. Cancer Metastasis Rev 2002; 21:17-27.
7. Partin AW, Brawer MK, Subong EN, Kelley CA, Cox JL, Bruzek DJ, et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis 1998; 1: 197-203.
8. Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol 1998; 159:1238-1242.
9. Morote J, Lorente JA, Encabo G. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. Cancer 1996; 78:2374-2378.
10. Cooper EH, Whelan P, Purves D. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. Prostate 1994; 25:236-242.
11. Gadre SG, Kale KU, Hedge R, Raste AS. Comparative study of alkaline phosphatase and prostate specific antigen in prostate cancer. Indian J Med Sci 2000; 54:136-139.
12. Berruti A, Dogliotti L, Mosca A, Gorzegno G, Bollito E, Mari M, et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol 2001; 12:S153-S157.
13. Tsao KC, Wu JT. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas. Clin Chim Acta 2001; 313:21-29.
14. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002; 167:512-515.
15. Lin H, McCulloch CE, Turnbull BW, Slate EH, Clark LC. A latent class mixed model for analysing biomarker trajectories with irregularly scheduled observations. Stat Med 2000; 19:1303-1318.
16. Slate EH, Turnbull BW. Statistical models for longitudinal biomarkers of disease onset. Stat Med 2000; 19:617-637.
17. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556.
18. Jennison C, Turnbull BW. Sequential equivalence testing and repeated confidence intervals, with applications to normal and binary responses. Biometrics 1993; 49:31-43.
19. Jennison C, Turnbull BW. Repeated confidence intervals for group sequential clinical trials. Control Clin Trials 1984; 5:33-45.
20. Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis 2003; 8:29-37.
21. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, et al. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res 2002; 62:5325-5335.
22. Early DS, Hill K, Burk R, Palmer I. Selenoprotein levels in patients with colorectal adenomas and cancer. Am J Gastroenterol 2002; 97:745-748.
23. Rimsza LM, Vela EE, Frutiger YM, Richter LC, Grogan TM, Bellamy WT. Combined in situ hybridization and immunohistochemistry for automated detection of cytomegalovirus and p53. Mol Diagn 1996; 1:291-296.
24. Rimsza LM, Vela EE, Frutiger YM, Rangel CS, Solano M, Richter LC, et al. Rapid automated combined in situ hybridization and immunohistochemistry for sensitive detection of cytomegalovirus in paraffin-embedded tissue biopsies. Am J Clin Pathol 1996; 106:544-548.
25. Grogan TM. Automated immunohistochemical analysis. Am J Clin Pathol 1992; 98:S35-S38.
26. Zhu Z, Kimura M, Itokawa Y, Aoki T, Takahashi JA, Nakatsu S, et al. Apoptosis induced by selenium in human glioma cell lines. Biol Trace Elem Res 1996; 54:123-134.
27. Zhong W, Oberley TD. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 2001; 61:7071-7078.
28. Sinha R, Kiley SC, Lu JX, Thompson HJ, Moraes R, Jaken S, et al. Effects of methylselenocysteine on PKC activity, cdk2 phosphorylation and gadd gene expression in synchronized mouse mammary epithelial tumor cells. Cancer Lett 1999; 146:135-145.
29. Montironi R, Magi Galluzzi CM, Marina S, Diamanti L. Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology. J Cell Biochem Suppl 1994; 19:238-245.
30. Montironi R, Magi-Galluzzi C, Fabris G. Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Pathol Res Pract 1995; 191:873-880.
31. Redman C, Scott JA, Baines AT, Basye JL, Clark LC, Calley C, et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett 1998; 125:103-110.
32. Hocman G. Chemoprevention of cancer: selenium. Int J Biochem 1988; 20:123-132.
33. Harrison PR, Lanfear J, Wu L, Fleming J, McGarry L, Blower L. Chemopreventive and growth inhibitory effects of selenium. Biomed Environ Sci 1997; 10:235-245.
34. Lu J, Jiang C. Antiangiogenic activity of selenium in cancer Chemoprevention: metabolite-specific effects. Nutr Cancer 2001; 40: 64-73.
35. Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 1999; 20:1657-1666.
36. Gasparian AV, Yao YJ, Lu J, Yemelyanov AY, Lyakh LA, Slaga TJ, et al. Selenium compounds inhibit I kappa B kinase (IKK) and nuclear factor-kappa B (NF-kappa B) in prostate cancer cells. Mol Cancer Ther 2002; 1:1079-1087.
37. Kretz-Remy C, Arrigo AP. Selenium: a key element that controls NF-kappa B activation and I kappa B alpha half life. BioFactors 2001; 14:117-125.
38. Kim YS, Milner J. Molecular targets for selenium in cancer prevention. Nutr Cancer 2001; 40:50-54.
39. Jiang C, Ganther H, Lu J. Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol Carcinog 2000; 29:236-250.
40. Huang YM, Liu S, Liu YX, Lin DJ, Duan CG, Li HW, et al. [An animal experiment and clinical investigation on the protective effect of selenium on the microcirculation induced by free radical damaged RBCs]. Sheng Li Xue Bao 1998; 50:315-325.
41. Chen Z, Fan Z, McNeal JE, Nolley R, Caldwell MC, Mahadevappa M, et al. Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol 2003; 169:1316-1319.
42. Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res 2002; 62:6812-6816.
43. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001; 61:5692-5696.
44. Jiang Z, Woda BA, Yang XJ. Alpha-methylacyl coenzyme A racemase as a marker for prostate cancer. J Am Med Ass2002; 287:3080-3081; author reply 3081.
45. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002; 62:2220-2226.
46. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. J Am Med Ass 2002; 287:1662-1670.
47. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 2000; 97:3207-3212.